Peter
Charles Hart is an Associate Professor of Pharmacology at the College of
Science, Health and Pharmacy, Roosevelt University. He received his PhD from
the University of Illinois at Chicago, where he investigated the role of
mitochondrial redox signaling in metabolic reprogramming of breast cancer. He
then pursued his postdoctoral research at the University of Chicago, where his
work focused on drug repurposing to target the tumor microenvironment of
ovarian cancer metastases. He is also a member of the Sigma Xi Scientific
Research Honor Society and the American Association of Colleges of Pharmacy. His
research program focuses on cell signaling involved in the development of
chemoresistance in breast and ovarian cancer. His laboratory specializes in 2D
and 3D cancer phenotyping to evaluate the mechanisms of action by which small
molecules may prevent tumor development, progression, and chemoresistance. The
lab is also well versed in assessing interactions between epithelial cancer
cells and the stroma (e.g., mesothelial cells, fibroblasts, endothelial cells).
Peter
Charles Hart is an Associate Professor of Pharmacology at the College of
Science, Health and Pharmacy, Roosevelt University. He received his PhD from
the University of Illinois at Chicago, where he investigated the role of
mitochondrial redox signaling in metabolic reprogramming of breast cancer. He
then pursued his postdoctoral research at the University of Chicago, where his
work focused on drug repurposing to target the tumor microenvironment of
ovarian cancer metastases. He is also a member of the Sigma Xi Scientific
Research Honor Society and the American Association of Colleges of Pharmacy. His
research program focuses on cell signaling involved in the development of
chemoresistance in breast and ovarian cancer. His laboratory specializes in 2D
and 3D cancer phenotyping to evaluate the mechanisms of action by which small
molecules may prevent tumor development, progression, and chemoresistance. The
lab is also well versed in assessing interactions between epithelial cancer
cells and the stroma (e.g., mesothelial cells, fibroblasts, endothelial cells).